Literature DB >> 23315213

Management of malignant pleural effusion.

Jack A Kastelik1.   

Abstract

Malignancy is one of the most common causes of pleural effusion. Malignant pleural effusion is defined by the presence of malignant cells in the pleural fluid. Development of malignant pleural effusion usually defines advanced malignancy. Pathophysiology of malignant pleural effusion is not fully understood and may involve complex interactions between the mesothelial and malignant cells. Investigations and management of patients with malignant pleural effusion require a multidisciplinary approach. In this review, current practice for management of patients with malignant pleural effusion will be discussed. In addition, imaging techniques will be covered, including the use of thoracic ultrasound and its role in image-guiding pleural procedures. Moreover, interventional techniques will be described, such as medical thoracoscopy, the use of indwelling pleural catheters, or surgery for investigation and management of malignant pleural effusion.

Entities:  

Mesh:

Year:  2013        PMID: 23315213     DOI: 10.1007/s00408-012-9445-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  146 in total

Review 1.  Thoracic ultrasonography for the pulmonary specialist.

Authors:  Seth J Koenig; Mangala Narasimhan; Paul H Mayo
Journal:  Chest       Date:  2011-11       Impact factor: 9.410

2.  Advanced medical thoracoscopy.

Authors:  G F Tassi; G P Marchetti; P L Aliprandi
Journal:  Monaldi Arch Chest Dis       Date:  2011-03

3.  Cytology of serous effusions. An investigation into the usefulness of cell blocks versus smears.

Authors:  A Dekker; P A Bupp
Journal:  Am J Clin Pathol       Date:  1978-12       Impact factor: 2.493

4.  Co-existent chylous and serous pleural effusions associated with ovarian cancer: a case report of Contarini's syndrome.

Authors:  F Lawton; G Blackledge; R Johnson
Journal:  Eur J Surg Oncol       Date:  1985-06       Impact factor: 4.424

Review 5.  Diagnosis of pleural effusion: a systematic approach.

Authors:  Emmet E McGrath; Paul B Anderson
Journal:  Am J Crit Care       Date:  2011-03       Impact factor: 2.228

6.  Malignant transient pleural transudate: a sign of early lymphatic tumoral obstruction.

Authors:  C Fernandez; C Martín; I Aranda; S Romero
Journal:  Respiration       Date:  2000       Impact factor: 3.580

7.  Pleural fluid analysis in chylous pleural effusion.

Authors:  Vishal Agrawal; Peter Doelken; Steven A Sahn
Journal:  Chest       Date:  2008-03-13       Impact factor: 9.410

8.  Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.

Authors:  Daniel Morgensztern; Saiama Waqar; Janakiraman Subramanian; Kathryn Trinkaus; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

9.  Prospective study to determine the volume of pleural fluid required to diagnose malignancy.

Authors:  Jennifer Swiderek; Samer Morcos; Vijayalakshmi Donthireddy; Rajesh Surapaneni; Vicki Jackson-Thompson; Lonni Schultz; Sudha Kini; Paul Kvale
Journal:  Chest       Date:  2009-09-09       Impact factor: 9.410

Review 10.  Serum and pleural fluid biomarkers for mesothelioma.

Authors:  Jenette Creaney; Bruce W S Robinson
Journal:  Curr Opin Pulm Med       Date:  2009-07       Impact factor: 3.155

View more
  22 in total

1.  Sarcopenia in patients with malignant pleural effusion: impact on symptoms, health status, and response to hospitalization.

Authors:  Janet Rodríguez-Torres; Laura López-López; Irene Cabrera-Martos; Gerald Valenza-Demet; Lawrence P Cahalin; Marie Carmen Valenza
Journal:  Support Care Cancer       Date:  2019-04-03       Impact factor: 3.603

2.  Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Qianjing Hu; Yongchun Shen; Dan Xu; Tao Wang; Fuqiang Wen
Journal:  Tumour Biol       Date:  2014-03-08

3.  Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion.

Authors:  Xue Pan; Anyuan Zhong; Yufei Xing; Minhua Shi; Bin Qian; Tong Zhou; Yongjing Chen; Xueguang Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

4.  Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.

Authors:  Jeong Su Cho; Kook Joo Na; Yongjik Lee; Yeong Dae Kim; Hyo Yeong Ahn; Chang Ryul Park; Young Chul Kim
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-12-04       Impact factor: 1.520

5.  Effectiveness and safety of diagnostic flexi-rigid thoracoscopy in differentiating exudative pleural effusion of unknown etiology: a retrospective study of 215 patients.

Authors:  Bao-An Gao; Gang Zhou; Li Guan; Ling-Yun Zhang; Guang-Ming Xiang
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

6.  Diagnostic value of CD206+CD14+ macrophages in diagnosis of lung cancer originated malignant pleural effusion.

Authors:  Xue-Bin Pei; Xiu-Zhi Wu; Feng-Shuang Yi; Kan Zhai; Huan-Zhong Shi
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

7.  Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Hongyu Long; Fuqiang Wen
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.379

8.  Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.

Authors:  Youngkyu Moon; Kyung Soo Kim; Jae Kil Park
Journal:  J Cardiothorac Surg       Date:  2015-10-28       Impact factor: 1.637

9.  Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma.

Authors:  Ying Tang; Lijun Xu
Journal:  J Exp Clin Cancer Res       Date:  2013-06-08

10.  Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis.

Authors:  Huan Xia; Xiao-Juan Wang; Qiong Zhou; Huan-Zhong Shi; Zhao-Hui Tong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.